Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #233 on Revance Therapeutics Inc (RVNC)
randychub
08/24/17 10:25 AM
#234 RE: Bickema #233
Double_Bagel
09/15/17 4:53 AM
#250 RE: Bickema #233
In the fall of 2016, we completed enrollment in the Phase II trial of RT002 to treat cervical dystonia, we expect the 24-week Phase II results in the coming weeks. You'll remember in the cervical dystonia interim results, our first cohort achieved higher reduction of symptoms and significantly longer duration effect than comparable studies completed with all other approved neurotoxins. In fact, the medium-duration effect was at least 24 weeks. We aspire to duplicate the strong results from cohort 1 and take the results to the U.S. and international regulatory authorities to discuss next steps. In March, we announced the completion of enrollment in our Phase III pivotal trials for RT002 injectable for glabellar lines and remain on track to report top line results in the fourth quarter of 2017. We fully expect to achieve statistically significant efficacy of 4 weeks on the primary end point as have all other approved neurotoxins. We are also pursuing the collection of secondary end points to obtain the 6-month duration claim. We plan to enter the $1 billion cosmetic neurotoxin market from a position of strength. We have been pursuing a global development strategy for glabellar lines, and we are planning to first file in the United States followed by Canada, Europe and Latin America.